Drug intelligence / Profile preview

icaridin

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Topical
01

Overview

Icaridin is a synthetic insect repellent belonging to the piperidine chemical family. Developed by Bayer in the 1980s, it is used topically on skin or clothing to repel mosquitoes, biting flies, ticks, chiggers, and fleas. Icaridin acts primarily by interfering with the olfactory system of insects—specifically odorant receptors and odorant binding proteins—thereby masking human scent cues and preventing host recognition. It does not kill insects but deters them from feeding or landing on treated surfaces. Icaridin is considered as effective as DEET but with lower risk of skin irritation and greater user acceptability. It has been approved for use in many countries since the early 2000s for protection against vector-borne diseases such as malaria, dengue fever, Zika virus, Lyme disease, West Nile fever, and others[1][3][5][7].

Brand names
picaridinTotalSTOP
Other names
hydroxy-ethyl isobutyl piperidine carboxylatesec-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate
02

Targets

AgamOBP1 (Anopheles gambiae odorant-binding protein 1)Orco (Odorant receptor co-receptor)

Beyond the preview

Go deeper on icaridin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on icaridin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call